Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in advanced solid tumors
NCT04047290Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivonescimab in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Incidence and nature of participants with adverse events and Number of participants with Dose-Limiting Toxicities at 4 weeks. Started Sep 2019; status: completed.
02
Drugs
ivonescimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04047290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047290.